# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Scott Fidel assumes Tenet Healthcare (NYSE:THC) with a Buy rating and announces Price Target of $224.
Keybanc analyst Scott Schoenhaus maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $2...
Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from ...
Cantor Fitzgerald analyst Sarah James reiterates Tenet Healthcare (NYSE:THC) with a Overweight and maintains $190 price target.
Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $208 to...